SEC62 and head and neck cancer: Based on findings of functional assays and genomic database analyses, SEC62 has been identified as a potential driver of ovarian, lung, prostate, and head and neck cancers, and high SEC62 expression has been correlated with significantly shorter disease-free survival and overall survival [8,9,14,16,17].